| Authors: |
Das K; Research Group GMP & T Cell Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Division of Virology, Innsbruck Medical University, Innsbruck, Austria.; Faculty of Biosciences, University Heidelberg, Heidelberg, Germany., Eisel D; Research Group GMP & T Cell Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, University Heidelberg, Heidelberg, Germany.; Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany., Vormehr M; Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany.; University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Müller-Decker K; Core Facility Tumor Models, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hommertgen A; Research Group GMP & T Cell Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Molecular & Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Jäger D; CCU Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medical Oncology, National Center for Tumor Diseases (NCT) and University Hospital Heidelberg, Heidelberg, Germany., Zörnig I; Department of Medical Oncology, National Center for Tumor Diseases (NCT) and University Hospital Heidelberg, Heidelberg, Germany., Feuerer M; Institute of Immunology, Regensburg Center for Interventional Immunology (RCI), University Regensburg and University Hospital Regensburg, Regensburg, Germany., Kopp-Schneider A; Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Osen W; Research Group GMP & T Cell Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany., Eichmüller SB; Research Group GMP & T Cell Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany. s.eichmueller@dkfz.de. |
